Medincell Announces Financial Calendar for 2026 and 2027
The biopharmaceutical group Medincell has announced the publication dates for its financial results for the fiscal year 2025-2026, as well as its general assembly and semi-annual results for 2026-2027, according to a statement released on Sunday.
According to the statement, the company will publish its annual results for the fiscal year 2025-2026, covering the period from April 2025 to March 2026, on Tuesday, June 16, 2026. The general assembly of shareholders will take place on Thursday, September 10, 2026. Finally, the results for the first half of the fiscal year 2026-2027, corresponding to the period April-September 2026, will be revealed on Tuesday, December 8, 2026. These three dates are the main milestones in the group's financial communication calendar for the coming months.
Medincell's Regulatory Success and Product Development
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Medincell is a biopharmaceutical licensing company that develops extended-release injectable treatments. The group received approval from the U.S. FDA for its extended-release risperidone treatment, initially for schizophrenia in April 2023, and then for bipolar I disorder in October 2025, the company states. This treatment utilizes the proprietary BEPO technology and is marketed in the United States by Teva under the name UZEDY. According to the statement, this same treatment also received approval for schizophrenia in Canada and South Korea in 2025.
Collaborative Efforts and Pipeline Development
Medincell's partner, Teva, submitted an application to the FDA in December 2025 for the authorization to market extended-release Olanzapine as a monthly treatment for adult schizophrenia, according to the group. Medincell reports collaborating with several pharmaceutical companies and foundations to develop its pipeline of drug candidates, which are at various stages of development. Based in Montpellier, the company employs more than 140 people representing over 25 different nationalities.
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
